Literature DB >> 24888599

SCIg vs. IVIg: let's give patients the choice!

K Samaan1, M C Levasseur, H Decaluwe, C St-Cyr, H Chapdelaine, A Des Roches, E Haddad.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24888599     DOI： 10.1007/s10875-014-0057-9

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN： 0271-9142            Impact factor:   8.317


× No keyword cloud information.
  16 in total

1.  Decision-making in the physician-patient encounter: revisiting the shared treatment decision-making model.

Authors:  C Charles; A Gafni; T Whelan
Journal:  Soc Sci Med       Date:  1999-09       Impact factor: 4.634

Review 2.  Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose.

Authors:  Melvin Berger
Journal:  Curr Opin Allergy Clin Immunol       Date:  2011-12

Review 3.  Intravenous immunoglobulin: adverse effects and safe administration.

Authors:  Hedi Orbach; Uriel Katz; Yaniv Sherer; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 4.  History of immunoglobulin replacement.

Authors:  Martha M Eibl
Journal:  Immunol Allergy Clin North Am       Date:  2008-11       Impact factor: 3.479

5.  Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home.

Authors:  Uwe Nicolay; Peter Kiessling; Melvin Berger; Sudhir Gupta; Leman Yel; Chaim M Roifman; Ann Gardulf; Florian Eichmann; Stefan Haag; Cordula Massion; Hans D Ochs
Journal:  J Clin Immunol       Date:  2006-01       Impact factor: 8.317

Review 6.  Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again.

Authors:  Richard L Wasserman
Journal:  J Clin Immunol       Date:  2012-07-25       Impact factor: 8.317

7.  Doctor-patient communication about drugs: the evidence for shared decision making.

Authors:  F A Stevenson; C A Barry; N Britten; N Barber; C P Bradley
Journal:  Soc Sci Med       Date:  2000-03       Impact factor: 4.634

8.  Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home.

Authors:  Ann Gardulf; Uwe Nicolay; Dipl Math; Oscar Asensio; Ewa Bernatowska; Andreas Böck; Beatriz T Costa-Carvalho; Carl Granert; Stefan Haag; Dolores Hernández; Peter Kiessling; Jan Kus; Nuria Matamoros; Tim Niehues; Sigune Schmidt; Ilka Schulze; Michael Borte
Journal:  J Allergy Clin Immunol       Date:  2004-10       Impact factor: 10.793

9.  Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin.

Authors:  Anders Fasth; Jeanette Nyström
Journal:  J Clin Immunol       Date:  2008-02-07       Impact factor: 8.317

10.  Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases.

Authors:  Lisa Kobrynski
Journal:  Biologics       Date:  2012-08-24
View more
  7 in total

1.  Quality of Life, Treatment Beliefs, and Treatment Satisfaction in Children Treated for Primary Immunodeficiency with SCIg.

Authors:  Serge Sultan; Émélie Rondeau; Marie-Claude Levasseur; Renée Dicaire; Hélène Decaluwe; Élie Haddad
Journal:  J Clin Immunol       Date:  2017-06-08       Impact factor: 8.317

2.  Cost Utility of Lifelong Immunoglobulin Replacement Therapy vs Hematopoietic Stem Cell Transplant to Treat Agammaglobulinemia.

Authors:  Di Sun; Jennifer R Heimall; Matthew J Greenhawt; Nancy J Bunin; Marcus S Shaker; Neil Romberg
Journal:  JAMA Pediatr       Date:  2022-02-01       Impact factor: 16.193

3.  Home-Based Subcutaneous Infusion of Immunoglobulin for Primary and Secondary Immunodeficiencies: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2017-11-01

4.  Home-Based Treatment with Immunoglobulins: an Evaluation from the Perspective of Patients and Healthcare Professionals.

Authors:  Chantal A Zuizewind; Paul van Kessel; Christine M Kramer; Mary M Muijs; Janneke C Zwiers; Mattanja Triemstra
Journal:  J Clin Immunol       Date:  2018-11-12       Impact factor: 8.317

5.  Biweekly Hizentra® in Primary Immunodeficiency: a Multicenter, Observational Cohort Study (IBIS).

Authors:  Alessandra Vultaggio; Chiara Azzari; Silvia Ricci; Baldassarre Martire; Valentina Palladino; Vera Gallo; Antonio Pecoraro; Claudio Pignata; Giuseppe Spadaro; Simona Graziani; Viviana Moschese; Antonino Trizzino; Giorgio Maria Boggia; Andrea Matucci
Journal:  J Clin Immunol       Date:  2018-06-28       Impact factor: 8.317

6.  Shared decision making: Does a physician's decision-making style affect patient participation in treatment choices for primary immunodeficiency?

Authors:  Christopher C Lamb; Yunmei Wang; Kalle Lyytinen
Journal:  J Eval Clin Pract       Date:  2019-05-22       Impact factor: 2.431

Review 7.  Patient Preferences for Subcutaneous versus Intravenous Administration of Treatment for Chronic Immune System Disorders: A Systematic Review.

Authors:  Paul M Overton; Natalie Shalet; Fabian Somers; Jeffrey A Allen
Journal:  Patient Prefer Adherence       Date:  2021-04-19       Impact factor: 2.711
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.